A growing body of research points to the role of the gut-brain axis in the development of Parkinson disease, with inflammatory bowel disease, leaky gut, and altered gut microbiota observed in the gut, often years before the onset of symptoms of Parkinson disease.
The USPSTF concludes that the evidence is lacking and that the balance of benefits and harms of cognitive impairment screening for older adults cannot be established.
In long-term care facilities, the rate of antipsychotic use in patients with PD ranges from 15% to 30%; however, the efficacy of AAPs in these patients has not been evaluated in large clinical trials.
Increased age, male gender, and the presence of baseline cerebral microbleeds is associated with increased risk for developing cerebral microbleeds in any location.
Compared with their peers, Asian patients with dementia were less likely to be prescribed antidementia drugs, and they received these drugs for fewer days per year.
The presence of objective subtle cognitive difficulties (Obj-SCD) on neuropsychological measures may predict faster amyloid accumulation and neurogenerative changes.
The FDA has approved an expanded indication for the Infinity™ Deep Brain Stimulation (DBS) system (Abbott) to include targeting the internal globus pallidus, which may lead to symptom improvement in patients with Parkinson disease.
Survey data published in JAMA Neurology indicate that approximately half of US adults perceive themselves to be at least somewhat likely to develop dementia.
